“Direct comparisons between flow and qPCR MRD targets – can they substitute for each other” Minimal Residual Disease as an Endpoint for Clinical Trials FDA Workshop March 4, 2013 - White Oak, Maryland, USA

Aktivitet: Tale eller præsentation - typerForedrag og mundtlige bidrag

Se relationer på Aarhus Universitet

Peter Hokland - Foredragsholder

4 mar. 2013

Ekstern organisation

NavnUnknown external organisation

ID: 52833950